Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of han nationality after rheumatic valve replacement: A ran-domized and controlled trial

International Journal of Medical Sciences

Volumn 9, Issue 6, 2012, Pages 472-479

  Wang, Ming Song ^a   Lang, Xi Long ^b   Cui, Shi Tao ^c   Fei, Ke ^d   Zou, Liang Jian ^b   Cao, Jia ^e   Wang, Liang Xu ^e   Zhang, Sheng Hui ^e   Wu, Xin Tian ^e   Wang, Yi Ling ^e   Ji, Qiang ^f  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d SHANGHAI PULMONARY HOSPITAL   (China)

^e TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^f TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Individualized warfarin therapy; Pharmacogenetics; Rheumatic valve surgery; Trial

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENE; GENETIC POLYMORPHISM; HEART VALVE REPLACEMENT; HUMAN; INTRACARDIAC THROMBOSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC HEART DISEASE; VKORC1 GENE;

ADULT; ALGORITHMS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; RHEUMATIC DISEASES; WARFARIN;

EID: 84866241369     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.4637     Document Type: Article

References (13)

1. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007, 21: 23-34.
2. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007, 120: 1-10.
3. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005, 106:135-140.
4. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105: 645-649.
5. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009, 19: 226-234.
6. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93:700-705.
7. Huang SW, Li Q, Zhu SY, Li L, Xiong F, Jia YK, Xu XM. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement. Clin Chem Lab Med 2009, 47: 26-31.
8. Veenstra DL, You JH, Rieder MJ, et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005, 15: 687-691.
9. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006, 79: 291-302.
10. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006, 79: 197-205.
11. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008, 83: 460-470.
12. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116: 2563-2570.
13. Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008, 84: 83-89.